Both systemic corticosteroid and IL-6 receptor (IL-6R) blockade (mainly tocilizumab) can rapidly reverse CRS symptoms and are commonly prescribed as front-line treatments for CRS. This evidence concerns the gene IL6R and congenital rubella syndrome.